[Quantification of T-lymphocyte subpopulations. Immunological marker in human immunodeficiency virus infections]. 1991

J E Brinchmann, and F Vartdal, and E Thorsby, and A Bucher, and S S Frøland, and P Kittelsen, and J Kristoffersen, and K Baklien
Institutt for transplantasjonsimmunologi, Rikshospitalet, Oslo.

The absolute number of CD4+ and CD8+ T cells was counted directly in the blood of 75 healthy controls and 223 individuals infected with human immunodeficiency virus (HIV). The HIV-seropositive individuals were also classified clinically according to the system recommended by the Centers for Disease Control. We observed a pattern of changes in the T cell subset counts of the patient group. This pattern could be defined by five T cell stages ranging from normal T cell subset values to values representing severe T cell immunodeficiency. A close correlation was observed between the immunological and clinical classification of the patients. Quantification of T cell subsets may provide useful information in the follow-up of individuals infected with HIV, particularly in assessing the indications for antiviral therapy, and its effects.

UI MeSH Term Description Entries
D007958 Leukocyte Count The number of WHITE BLOOD CELLS per unit volume in venous BLOOD. A differential leukocyte count measures the relative numbers of the different types of white cells. Blood Cell Count, White,Differential Leukocyte Count,Leukocyte Count, Differential,Leukocyte Number,White Blood Cell Count,Count, Differential Leukocyte,Count, Leukocyte,Counts, Differential Leukocyte,Counts, Leukocyte,Differential Leukocyte Counts,Leukocyte Counts,Leukocyte Counts, Differential,Leukocyte Numbers,Number, Leukocyte,Numbers, Leukocyte
D006679 HIV Seropositivity Development of neutralizing antibodies in individuals who have been exposed to the human immunodeficiency virus (HIV/HTLV-III/LAV). AIDS Seroconversion,AIDS Seropositivity,Anti-HIV Positivity,HIV Antibody Positivity,HIV Seroconversion,HTLV-III Seroconversion,HTLV-III Seropositivity,AIDS Seroconversions,AIDS Seropositivities,Anti HIV Positivity,Anti-HIV Positivities,Antibody Positivities, HIV,Antibody Positivity, HIV,HIV Antibody Positivities,HIV Seroconversions,HIV Seropositivities,HTLV III Seroconversion,HTLV III Seropositivity,HTLV-III Seroconversions,HTLV-III Seropositivities,Positivities, Anti-HIV,Positivities, HIV Antibody,Positivity, Anti-HIV,Positivity, HIV Antibody,Seroconversion, AIDS,Seroconversion, HIV,Seroconversion, HTLV-III,Seroconversions, AIDS,Seroconversions, HIV,Seroconversions, HTLV-III,Seropositivities, AIDS,Seropositivities, HIV,Seropositivities, HTLV-III,Seropositivity, AIDS,Seropositivity, HIV,Seropositivity, HTLV-III
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D016176 T-Lymphocyte Subsets A classification of T-lymphocytes, especially into helper/inducer, suppressor/effector, and cytotoxic subsets, based on structurally or functionally different populations of cells. T-Cell Subset,T-Cell Subsets,T-Lymphocyte Subset,Subset, T-Cell,Subset, T-Lymphocyte,Subsets, T-Cell,Subsets, T-Lymphocyte,T Cell Subset,T Cell Subsets,T Lymphocyte Subset,T Lymphocyte Subsets

Related Publications

J E Brinchmann, and F Vartdal, and E Thorsby, and A Bucher, and S S Frøland, and P Kittelsen, and J Kristoffersen, and K Baklien
December 1992, American journal of obstetrics and gynecology,
J E Brinchmann, and F Vartdal, and E Thorsby, and A Bucher, and S S Frøland, and P Kittelsen, and J Kristoffersen, and K Baklien
January 1988, Voprosy virusologii,
J E Brinchmann, and F Vartdal, and E Thorsby, and A Bucher, and S S Frøland, and P Kittelsen, and J Kristoffersen, and K Baklien
January 1997, Molecular medicine (Cambridge, Mass.),
J E Brinchmann, and F Vartdal, and E Thorsby, and A Bucher, and S S Frøland, and P Kittelsen, and J Kristoffersen, and K Baklien
September 1979, Thymus,
J E Brinchmann, and F Vartdal, and E Thorsby, and A Bucher, and S S Frøland, and P Kittelsen, and J Kristoffersen, and K Baklien
March 1985, Scandinavian journal of immunology,
J E Brinchmann, and F Vartdal, and E Thorsby, and A Bucher, and S S Frøland, and P Kittelsen, and J Kristoffersen, and K Baklien
August 2008, AIDS research and human retroviruses,
J E Brinchmann, and F Vartdal, and E Thorsby, and A Bucher, and S S Frøland, and P Kittelsen, and J Kristoffersen, and K Baklien
July 2008, The Pediatric infectious disease journal,
J E Brinchmann, and F Vartdal, and E Thorsby, and A Bucher, and S S Frøland, and P Kittelsen, and J Kristoffersen, and K Baklien
November 1980, Clinical and experimental immunology,
J E Brinchmann, and F Vartdal, and E Thorsby, and A Bucher, and S S Frøland, and P Kittelsen, and J Kristoffersen, and K Baklien
June 1988, Oral surgery, oral medicine, and oral pathology,
J E Brinchmann, and F Vartdal, and E Thorsby, and A Bucher, and S S Frøland, and P Kittelsen, and J Kristoffersen, and K Baklien
March 1981, The Journal of clinical endocrinology and metabolism,
Copied contents to your clipboard!